These results are clinically meaningful – they suggest that ZDHHC9 might serve as a negative predictor of immunotherapy efficacy in BC, where low expression denotes a favorable immune contexture and higher chance of benefit from ICIs. Here, ZDHHC9 is linked to breast cancer.